Avalon GloboCare Corp. and Avactis Biosciences Establish Joint Venture with Arbele Limited to Co-Develop Next-Generation Multi-Targeted CAR-T Cellular Immunotherapy
January 03, 2019 at 09:00 am EST
Avalon GloboCare Corp. announced that the Company and Avactis Biosciences, have entered into a joint venture and exclusive license agreement with Arbele Limited to co-develop next generation, transposon-based Chimeric Antigen Receptor (CAR)-T and CAR-Natural Killer (NK) cellular therapies. These unique CAR vector constructs are non-virally engineered, possessing multiple therapeutic targets as well as unique “safety-switch" mechanisms. Based on Avalon’s extensive hospital network for cellular therapy, together with the Company’s established GMP bio-production facility in China (Epicon Biotech, Nanjing), this joint venture allows Avalon to accelerate the clinical development of more efficacious and safer CAR-T/CAR-NK therapies, such as those developed by Arbele.